On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.915 USD | +1.84% | +4.28% | +20.71% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
43.95 CNY | +0.57% | +5.32% | 2.55B | ||
6.915 USD | +1.84% | +4.28% | 467M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.71% | 467M | |
+20.97% | 46.4B | |
-0.67% | 41.75B | |
+48.54% | 41.37B | |
-3.52% | 29.71B | |
+10.66% | 26.01B | |
-19.95% | 19.52B | |
+30.82% | 12.43B | |
+0.46% | 12.18B | |
-0.07% | 12.13B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.